Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 49.41 | -19.02 | 17.15 | 13.65 | 10.76 |
| Net Profit | 13.48 | -26.11 | 20.93 | 16.32 | 11.28 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-24 | Dec-23 |
| EBIT-Margin
| -17,335.17 | -9,269.05 | -- | -- | -- |
| Net Margin
| -481,225.00 | -265,851.24 | -- | -- | -- |
| Return on equity
| -108.01 | -99.72 | -- | -148.97 | -83.70 |
| Return on Capital
| -53.04 | -55.31 | -- | -60.85 | -47.01 |
| Return on Assets
| -46.20 | -48.22 | -51.89 | -50.29 | -41.95 |
| Debt to Equity (x)
| -- | -- | 0.00 | 3.62 | 0.95 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
-60.85
|
-47.01
|
-51.25
|
-47.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
-148.97
|
-83.70
|
-91.36
|
-84.30
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-51.89
Lower than Peers by 20.91
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
-51.89
|
-50.29
|
-41.95
|
-46.37
|
-42.73
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
-17,335.17
|
-1,202.93
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
-481,225.00
|
-1,255.00
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
-1.00
|
-0.95
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
17.15
Higher than Peers by 17.95
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
17.15
|
18.96
|
5.98
|
28.91
|
37.82
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
20.93
Higher than Peers by 28.23
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
20.93
|
34.80
|
30.97
|
3.82
|
34.65
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
3.62
|
0.95
|
0.71
|
0.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-18.68
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
-18.68
|
--
|
0.12
|
0.19
|
0.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.95
Lower than Peers by 3.86
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
1.95
|
2.62
|
5.94
|
4.92
|
5.45
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.95
Lower than Peers by 3.75
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
1.95
|
--
|
--
|
4.93
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
-15.69
|
-11.50
|
-18.11
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
99.58
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
0.00
|
0.03
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
363.70
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
-4.36
|
-39.37
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
29.39
|
316.24
|
288.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
8.09
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
2.59
Lower than Peers by 2.59
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
2.59
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.23
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
-0.23
|
-0.01
|
0.43
|
1.22
|
0.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3
Lower than Peers by 143
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
3
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|